A 43-year-old woman...stage IVa (T2bN2M1b) lung adenocarcinoma...Three different mutation type were detected, including the classical EML4-ALK fusion, the ALK G1202R acquired resistance mutation and a new fusion form of NTRK rearrangement (LIPI-NTRK1)...Ultimately, This patient had a progression-free survival of 7 months with crizotinib but of only one month with brigatinib treatment.